Trial Profile
A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid) Regimen or a Sequential Azacitidine (Vidaza) Plus Lenalidomide (Revlimid) Regimen Versus Conventional Care Regimens for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 17 Oct 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 1 May 2018 to 5 May 2018.
- 02 Feb 2017 Planned End Date changed from 1 Apr 2018 to 1 May 2018.